Australian researchers have discovered a potential new lifeline for the tiniest and most vulnerable newborns. Scientists at ...

Late-breaking research reveals there is no benefit from high-dose chemotherapy followed by autologous stem cell transplant ...

The Global Autologous Cell Therapy Market has seen significant growth and is expected to continue expanding with a projected CAGR of 18.1% from 2019 to 2027, reaching a market value of approximately ...

SAN DIEGO -- Results from a small single-center study showed that treatment with a gene therapy involving the use of ...

Late-breaking research finds no survival benefit from autologous stem cell transplant in mantle cell lymphoma patients with ...

Two million bone transplants are performed worldwide yearly, including half a million in the United States alone. Yet, a ...

Autologous stem cell transplant plus Rituxan did not improve survival outcomes in certain patients with mantle cell lymphoma compared with Rituxan alone.

Trial is evaluating VIPER-101, a novel, gene edited, autologous dual-population CAR-T therapy in patients with T cell lymphomaVIPER-101 was ...